Podcasts about Prognosis

Optimistic bias by a family member charged with healthcare decisions can be a barrier for your wishes to be carried out. Learn how to avoid it in your advance care planning: https://bit.ly/499XQqaWhen Families Don't Hear the Truth: Why We Ignore Poor Prognoses  When someone we love is critically ill, we hang on every word from the medical team. But research shows something surprising and unsettling: when the prognosis is poor, many families simply don't hear it. Not because they aren't listening, and not because doctors aren't communicating clearly, but because human psychology steps in to protect us from unbearable news. Learn Important Facts to Guide You in Your Advance Care Planning Listen to learn more about this phenomenon and important considerations when you chose your healthcare decisionmaker. We also rebroadcast the S4E52 episode about preparing your paperwork for decisionmakers to speak for you when you are unable to.#AdvanceCarePlanning #EndofLife #ICU #HealthcareProxy #DurablePowerofAttorney #HealthcareDecisions #EveryoneDiesthePodcast #EveryDayisaGift #LivingWill #AdvanceDirective #PoorPrognosisIn this Episode:00:20 - How Appointed Decision Makers Interpret Information About Prognosis01:51 - Why Do Some Family Members Push for Every Possible Treatment When Further Interventions are Futile?03:35 - How Unrealistic Optimism Affects Decisions in the ICU07:36 - Intro - S4E52 - Durable Power of Attorney12:40 - Overlooked No More: Cordell Jackson20:36 - Are You Prepared to Die?  Get Ideas for Your Advance Care Planning 22:54 - The Importance of an Advance Directive39:47 - Advance Care Planning Example - How to Be Thorough and Precise 50:44 - OutroSupport the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Differences in Severity and Prognosis Between Bicuspid and Tricuspid Severe Aortic Stenosis.

In part six of this seven-part series on FND, Dr. Jon Stone and Dr. Gabriela Gilmour discuss the prognosis of functional neurologic disorders.  Show citation:  Gelauff J, Stone J. Prognosis of functional neurologic disorders. Handb Clin Neurol. 2016;139:523-541. doi:10.1016/B978-0-12-801772-2.00043-6  Show transcript:  Dr. Jon Stone: This is Jon Stone with the Neurology Minute. Gabriela Gilmour and I are back to continue with part six of our seven-part series on FND. Today we're going to talk about prognosis. What's the outlook for people with FND? It's obviously a question that patients and relatives desperate to know the answer. Gabriela, what do you say to your patients with FND when they say, "What's going to happen to me? Dr. Gabriela Gilmour: That's a difficult question because the prognosis is variable and I'll talk in a moment about what we know about prognosis from the literature. But I think when patients ask me what's going to happen, I try to instill hope because we do know that this is a condition that can improve and it can improve, especially when patients have access to rehabilitation programs or psychotherapy or other treatment plans. So I try to emphasize that piece and emphasize hope when I'm talking about that with my patients. But if we sort of take a step back and we look at what is the overall prognosis from what we know in the literature with FND, fundamentally, FND for many is a chronic and often relapsing condition. As I mentioned, it can certainly improve with rehabilitation. A challenge is that most of our published studies on the prognosis of FND really come from a time when we knew a lot less about the condition and we had fewer treatment options. So these studies are somewhat difficult to apply today, but in these studies, we see that at least without treatment, most patients are the same or worse at follow-up. However, now we're starting to develop more rehabilitation programs and we have more evidence that shows that people certainly improve with rehabilitation and with therapy. There are some factors that I try to emphasize to patients as being good prognostic factors when I'm talking with them. These may be things like younger age, a shorter duration between symptom onset and diagnosis and patient agreement with the diagnosis or the perception of having control over their illness. When these types of things are present, I try to highlight them to, again, help build that hope for recovery. The one thing that I would also add maybe a bit of a different question, but I think is important to mention is that we as neurologists still have a lot to provide to our patients, even those who may not see much recovery in their symptoms and live with chronic illness. It's really important to consider that regular check-ins. In these check-ins, we can monitor for changing perpetuating factors. We can facilitate social services, mobility aids that help overall quality of life. We can still offer a lot to our patients. The other piece that I would mention too is that our patients are at risk of iatrogenic harm. So there is definitely a role for the neurologist to look at, are there medications that might not be indicated that are causing harm? Are there other things that we can communicate clearly with other care providers to make sure that we reduce that risk for our patients? Dr. Jon Stone: So it's about balancing some realism, but also making sure the patient doesn't lose hope. A good outcome isn't always necessarily that symptoms gone away. It might be similar to other chronic neurological conditions that we look after where we're okay with an outcome where the patient still has symptoms if they understand their condition and can learn to live with it better. We'll be back for our final Neurology Minute episode on FND with myself and Gabriela Gilmour talking about future directions in FND. Thanks for listening.

Drs Joseph Mikhael and Shaji Kumar discuss the future of multiple myeloma, including enhanced diagnostics for detecting myeloma, frontline therapy, and durable responses. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002718. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Myeloma https://emedicine.medscape.com/article/204369-overview Updated Diagnostic Criteria and Staging System for Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/27249749/ Mass Spectrometry for the Evaluation of Monoclonal Proteins in Multiple Myeloma and Related Disorders: An International Myeloma Working Group Mass Spectrometry Committee Report https://pubmed.ncbi.nlm.nih.gov/33563895/ Multiple Myeloma Imaging https://emedicine.medscape.com/article/391742-overview Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis https://pubmed.ncbi.nlm.nih.gov/34299097/ Monoclonal Gammopathy of Undetermined Significance https://www.ncbi.nlm.nih.gov/books/NBK507880/ Primary Plasma Cell Leukemia: Consensus Definition by the International Myeloma Working Group According to Peripheral Blood Plasma Cell Percentage https://pubmed.ncbi.nlm.nih.gov/34857730/ Advancing MRD Detection in Multiple Myeloma: Technologies, Applications, and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/40214184/ Genomic Landscape of Multiple Myeloma and Its Precursor Conditions https://pubmed.ncbi.nlm.nih.gov/40399554/  Quadruplet Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/39348665/ Subcutaneous Daratumumab (Dara) + Bortezomib/Lenalidomide/Dexamethasone (VRd) With Dara + Lenalidomide (DR) Maintenance in Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Sustained Minimal Residual Disease Negativity in the Phase 3 PERSEUS Trial https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7501 Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial https://pubmed.ncbi.nlm.nih.gov/39841461/ Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant Is Not a Medically Suitable Treatment https://www.clinicaltrials.gov/study/NCT05561387 Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy https://pubmed.ncbi.nlm.nih.gov/34002066/ The Role of CELMoD Agents in Multiple Myeloma https://pmc.ncbi.nlm.nih.gov/articles/PMC12399888/ Phase 2 Study of Talquetamab + Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma and Extramedullary Disease: REDIRECTT-1 https://library.ehaweb.org/eha/2025/eha2025-congress/4173809/shaji.kumar.phase.2.study.of.talquetamab.2B.teclistamab.in.patients.with.html Discovery of a Novel Class NSD2 Inhibitor for Multiple Myeloma With t(4;14) https://pubmed.ncbi.nlm.nih.gov/40949769/ Long-Term (≥5 Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel (Cilta-Cel) in CARTITUDE-1 Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7507

December 15, 2025 - Season 16, Episode 63 of The Terrible Podcast is now in the can. In this Monday morning episode, Alex Kozora and I get right to talking about the Pittsburgh Steelers as they prepare to play the Miami Dolphins Monday night to close out Week 15 of the 2025 NFL regular season. Alex and I quickly update the latest concerning Steelers OLB T.J. Watt, who is currently recovering from a partially collapsed lung that happened during a procedure late last week. We discuss Watt being officially ruled out for the Monday night game versus the Dolphins and what his prognosis for more missed games may or may not be. In addition to Watt, the Steelers have two other players that have been ruled out for Monday night in addition to two others being listed as questionable. Those two questionable players are DT Derrick Harmon (knee) and RB Jaylen Warren (illness), who was added to the team's injury report during this show. The Steelers are sure to have some transactions announced on Monday so Alex and I go over what those moves might possibly look like. We do, however, get news during the show that WR Marquez Valdes-Scantling will be signed off the team's practice squad later in the day. After going over a lot of housekeeping early in this show, Alex and I then welcome Hal Habib back to the podcast. Habib covers the Dolphins for The Palm Beach Post, and he is in Pittsburgh on Monday to cover the Monday night game. We spend 30 minutes with Habib discussing the Dolphins season to date in addition to previewing the Monday night game between Miami and Pittsburgh. He gives us his insight into the Dolphins when it comes to both sides of the football ahead of the Monday night game. At the end of our interview with Hal, he kindly gives us his score prediction for the Monday night game. If not already doing so, please follow Hal on Twitter/X at @gunnerhal and please make sure to read his work online here: https://www.palmbeachpost.com/staff/3294661001/hal-habib/. After finishing our interview with Hal, Alex and I then give our breakdown and complete preview of the Monday night game between the Steelers and the Dolphins. We also give out score predictions for the Monday night game to wrap up that segment. Finally, Alex and quickly go over what else transpired in the NFL on Sunday and how the Week 18 game between the Steelers and the Baltimore Ravens still figures to be one where the winner goes to the playoffs and the loser stays home for the postseason. This 95-minute episode also discusses several other minor topics not noted above and we end this episode by answering an email we received from a listener. steelersdepot.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Acoustic pleasure returns today and we are pleased to welcome back Erik Bruce. Its been a while since we had Erik on and since then he has gone from strength to strength. With releases on labels such as Prognosis, Affiliate and Capital Heaven plus gigs all over the place 2025 has been a pretty decent year for Erik all in all. He also recently played for Stage one in Shorditch alongside the legendary Nick Muir! Erik has crafted a mix full of atmospheric prog we know you will love while your show host has created a set loaded with goodies that youll want to unwarp this December!

Welcome to the Part Time Pilot Audio Ground School Podcast! This podcast releases a 2 new episodes every week on Mondays and Wednesdays. Every Monday, we release an episode that is the next lesson of our IFR Online Ground School. Every Wednesday, we release an episode that is the next lesson of our Private Pilot Online Ground School.    We are working our way through both Online Ground Schools for students to listen to ground school for FREE! If you don't want to wait for new podcasts or you don't want to hear ads or course updates, you can join us in our VIP podcast. In order to join the VIP podcast, you must purchase our Online Ground School. When you do, you'll get sent an email invite to the VIP podcast to download and listen on your favorite podcast app, plus all the amazing lifetime features inside our Online Ground Schools (lessons, videos, audio, quizzes, practice tests, flash cards, test prep PDFs, grade tracking, digital notes, trained AI instructor chat, 7-day a week email support, online study group, scholarships and more).    The #1 reason student pilots never end up becoming a private pilot is NOT due to money. The real reason is actually deeper than that. Yes, flight training is expensive. But every student pilot knows this and budgets for it when they decide to do it.   The actual #1 reason a student pilot fails is because they do not have a good, fundamental understanding of the private pilot knowledge they are meant to learn in ground school.    You see when a student does not have a good grasp of this knowledge they get to a point in their flight training where their mind just can't keep up. They start making mistakes and having to redo lessons. And THAT is when it starts getting too expensive.    This audio ground school is meant for the modern day student pilot... aka the part time student pilot. Let's face it, the majority of us have full time responsibilities on top of flight training. Whether it is a job, kids, family, school, etc. we all keep ourselves busy with the things that are important to us. And with today's economy we have to maintain that job just to pay for the training. The modern day student pilot is busy, on the go and always trying to find time throughout his or her day to stay up on their studies. The audio ground school allows them to consume high quality content while walking, running, working out, sitting in traffic, traveling, or even just a break from the boring FAR/AIM or ground school lecture.    Did I meant high quality content? The audio ground school is taken straight out of the 5-star rated Part Time Pilot Online Ground School that has had over 2000 students take and pass their Private Pilot & IFR exams with only 2 total students failing the written. That's a 99.9% success rate! And the 2 that failed? We refunded their cost of ground school and helped them pass on their second attempt. We do this by keeping ground school engaging, fun, light and consumable. We have written lessons, videos, audio lessons, live video lessons, community chats, quizzes, practice tests, flash cards, study guides, eBooks and much more.   Part Time Pilot was created to be a breath of fresh air for student pilots. To be that flight training provider that looks out for them and their needs. So that is just what we are doing with this podcast.    Private Pilot - Section 5 - Lesson #16: In this FREE Private Pilot online ground school audio lesson we cover the topic of signicant and prognosis weather charts as well as other wide area charts used by the FAA and pilots around the US for flight planning.    Links mentioned in the episode:   Aviation Weather: https://aviationweather.gov/sigwx/ 1800WXBrief: https://www.1800wxbrief.com/Website/weatherGraphics?conus=0  PPL study group: https://www.facebook.com/groups/parttimepilot  IFR study group: https://www.facebook.com/groups/parttimepilotifr/  Recommended Products & Discounts:  https://parttimepilot.com/recommended-products-for-student-pilots/ 

What does body dysmorphic disorder (BDD) look like in young people? In Part 3, Katharine Phillips discusses developmental differences in symptoms across children, adolescents, and diverse cultural or gender groups. She outlines early warning signs, risk factors that shape long-term outcomes, and how clinicians can distinguish BDD from related disorders such as obsessive-compulsive disorder and social anxiety, a vital conversation for anyone involved in paediatric mental health.  Timestamps:  00:50 – Age differences  03:55 – Warning signs  07:15 – Social media  08:42 – Prognosis  10:17 – Obsessive-compulsive disorder  14:15 – Future of BDD 

We review BRUEs (Brief Resolved Unexplained Events). Hosts: Ellen Duncan, MD, PhD Noumi Chowdhury, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/BRUE.mp3 Download Leave a Comment Tags: Pediatrics Show Notes What is a BRUE? BRUE stands for Brief Resolved Unexplained Event. It typically affects infants 60 days old Gestational Age: GA > 32 weeks (and Post-Conceptional Age > 45 weeks) Frequency: This is the first episode Duration: Lasted < 1 minute Intervention: No CPR performed by a trained professional Clinical Picture: Reassuring history and physical exam Management for Low Risk: Generally do not require extensive testing or admission. Prioritize safety education/anticipatory guidance. Ensure strict return precautions and close outpatient follow-up (within 24 hours). High Risk Criteria Any infant not meeting the low-risk criteria is automatically High Risk. Additional red flags include: Suspicion of child abuse History of toxin exposure Family history of sudden cardiac death Abnormal physical exam findings (trauma, neuro deficits) Management for High Risk: Requires a more thorough evaluation. Often requires hospital admission. Note: Serious underlying conditions are identified in approx. 4% of high-risk infants. Differential Diagnosis: “THE MISFITS” Mnemonic T – Trauma (Accidental or Non-accidental/Abuse) H – Heart (Congenital heart disease, dysrhythmias) E – Endocrine M – Metabolic (Inborn errors of metabolism) I – Infection (Sepsis, meningitis, pertussis, RSV) S – Seizures F – Formula (Reflux, allergy, aspiration) I – Intestinal Catastrophes (Volvulus, intussusception) T – Toxins (Medications, home exposures) S – Sepsis (Systemic infection) Workup & Diagnostics Step 1: Stabilization ABCs (Airway, Breathing, Circulation) Point-of-care Glucose Cardiorespiratory monitoring Step 2: Diagnostic Testing (For High Risk/Symptomatic Patients) Labs: VBG, CBC, Electrolytes. Imaging: CXR: Evaluate for infection and cardiothymic silhouette. EKG: Evaluate for QT prolongation or dysrhythmias. Neuro: Consider Head CT/MRI and EEG if there are concerns for trauma or seizures. Clinical Pearl: Only ~6% of diagnostic tests contribute meaningfully to the diagnosis. Be judicious—avoid “shotgunning” tests in low-risk patients. Prognosis & Outcomes Recurrence: Approximately 10% (lower than historical ALTE rates of 10-25%). Mortality: < 1%. Nearly always linked to an identifiable cause (abuse, metabolic disorder, severe infection). BRUE vs. SIDS: These are not the same. BRUE: Peaks < 2 months; occurs mostly during the day. SIDS: Peaks 2–4 months; occurs mostly midnight to 6:00 AM. Take-Home Points Diagnosis of Exclusion: You cannot call it a BRUE until you have ruled out obvious causes via history and physical. Strict Criteria: Stick strictly to the Low Risk criteria guidelines. If they miss even one (e.g., age < 60 days), they are High Risk. Education: For low-risk families, the most valuable intervention is reassurance, education, and arranging close follow-up. Systematic Approach: For high-risk infants, use a structured approach (like THE MISFITS) to ensure you don’t miss rare but reversible causes. Read More

Salut à tous, Voici la tracklist de cette premiere. Au programme, de la house, de la progressive et de la melodic techno avec des labels comme Prognosis, Bedrock, Brique Rouge ou encore Code QR. Si vous voulez me contacter pour que je joue vos morceaux ou autre: xaric150@gmail.com Le label mis en avant ce mois-ci: Brique Rouge Brique Rouge est un label français créé par David Duriez en 1999. A l’origine, il était orienté House et a vite reçu les éloges de la scène internationale. Durant le confinement, David Duriez a décidé de relancer le label en l’ouvrant aux styles qu’il affectionne et sans contraintes. Depuis, il enchaîne une sortie par semaine, disponible sur le bandcamp du label en avant première et ensuite sur les plateformes de téléchargements légales. Tracklist: 01 – Doug Crawford – Haze (Sean McClellan Vapor Mix) – PROGNOSIS 02- Mzala Wa Afrika – Ingonyama (Original Afromix) – Ostowana 03- Sam T Harper – Our Last Dance – Critical Elements 04- PREXSE – Pyrite (Original Mix) – Tanzgemeinschaft 05- Amy Winehouse – Valerie (Keybe Remix) – White 06- Steve Sibra – Endless Plains – Brique Rouge 07- Aymeric T – Trilead – Brique Rouge 08- CJW – Sunbeats – Rhythm Cult 09- Carlos Nilmmns – Riviera – COD3 QR 10- Ciava – Higher (Extended Mix) – FER Music 11- Eachother – Disco Bitch (Original Mix) – Flashmob Records 12- Golden Factory Gang & Alex P Bickel – To Be Nowhere (Kickbugs Remix) – Golden Factory Records 13- Sum Bloke – Brothers (Extended Mix) – Quincy Boy Records 14- John Fritz – Grooving – Brique Rouge 15- Phil Weeks – When My Soul Wears Through (Original Mix) – Robsoul Recordings 16- Bram VanK & Ïtrema – Saxy Lady – Brique Rouge 17- Jaques Le Noir – Level (Seumas Norv Remix) – Bellosguardo 18- David Morales, Cevin Fisher, Romina Johnson – Sunshine (Extended) – DIRIDIM 19- Skatman- Man In The Mirror – COD3 QR 20- Lois (FR) – Quintessence – COD3 QR 21- Oxia – Not Sure – Van Czar Series 22- Jay Robinson & Majestic – The Deacon – COD3 QR 23- Costello – Tangerine Boy – COD3 QR 24- SOUTHSONIKS – Ex Animo – A-TRACTION records 25- DCLVIII OFC – Countdown – COD3 QR 26- Tokyo Fan Club – Circles (Marc Romboy Remix) – Bedrock Records 27- Micah & Paul Lukasewich Feat. Kiki Cave – Evening Winds (Original Mix) – Balance Music 28- Jondi & Spesh – Hold Me Close (Original Mix) – Looq Records 29- Bedrock – Heaven Scent (Rodriguez Jr. remix) – Bedrock Records

We all want a little treat—even if we're on a budget. That desire may be part of what's shaping U.S. liquor sales; big spirits companies are seeing growth in the sales of their smaller bottles of liquor, while sales of the pricier larger sizes decline. What does that tell us about how consumers are feeling about their wallets? Host Alex Ossola discusses with Nadine Sarwat, director and equity research analyst at brokerage firm Bernstein. And finally, in this last episode of our alternative economic indicator series, WSJ investing columnist Spencer Jakab joins Alex to take stock of all four indicators in this series—Nevada employment, copper, heavy trucks and liquor—and the picture they paint about the broader U.S. economy.  Sign up for the WSJ's free What's News newsletter. Further Listening Alternative Indicators: Can Nevada Employment Predict Where the Economy is Headed? Alternative Indicators: What's Dr. Copper's Prognosis for the U.S. Economy? Alternative Indicators: What Big-Rig Truck Sales Reveal About the U.S. Economy Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textHow far can AI go in helping us diagnose disease—without losing the human judgment patients rely on?In this episode, I break down four studies shaping the future of digital pathology, oncology, and neurology. From spatial biology updates at SITC to voice-based Alzheimer's detection, deep learning for sarcoma prognosis, and new guidelines for safe AI deployment, this week's digest highlights where AI is making a real impact—and where caution still matters.Episode Highlights1️⃣ SITC Trends & Spatial Biology (00:00 → 07:40)I share key updates from SITC 2025, including the growing role of multiplex immunofluorescence (mIF) and the need for integrated staining-to-scanning workflows. I also preview new educational content and upcoming podcast guests in global AI research.2️⃣ Digital Neuropathology & Alzheimer's (07:40 → 13:01)A major review confirms that digital neuropathology is now robust enough for large-scale Alzheimer's studies—opening doors for computational tools to link histology with cognition.3️⃣ Patient Safety in AI (13:01 → 19:56)An Italian review underscores the foundations of trustworthy AI: dataset quality, transparency, oversight, and continuous validation. I discuss why “patient-centered AI” must remain our standard.4️⃣ Voice Biomarkers for Cognitive Decline (19:56 → 26:43)AI models analyzing short speech recordings are showing high accuracy for early Alzheimer's detection. This could make future screening simple, noninvasive, and more accessible.5️⃣ Deep Learning for Sarcoma Prognosis (34:06 → 35:59)A multi-instance CNN outperforms FNCLCC grading by identifying prognostic patterns in tumor center and periphery regions, offering new insights into soft-tissue sarcoma biology.TakeawaysmIF is maturing quickly but needs standardized, end-to-end workflows.Digital neuropathology is ready for broader Alzheimer's research.Safe AI requires multidisciplinary collaboration and rigorous validation.Voice biomarkers may become powerful tools for early cognitive assessment.Deep learning can refine prognosis and reveal hidden tumor patterns.ResourcesHamamatsu (MoxiePlex) • Biocare Medical (ONCORE Pro X) • SITC Programs • Recent publications on AI biomarkers and computational pathology.Thanks for listening—and for being part of this growing digital pathology community.Support the showGet the "Digital Pathology 101" FREE E-book and join us!

Dame Jilly Cooper died of an acute subdural haematoma, following a fall.   Pathways for CT head in adults exist to guide us in determining who needs a CT, but we must not forget the importance of safety netting all elderly people after head injury and to consider measures to prevent patients sustaining head injuries in the first place.   Check out the papers mentioned.   Evans LR, Jones J, Lee HQ, Gantner D, Jaison A, Matthew J, Fitzgerald MC, Rosenfeld JV, Hunn MK, Tee JW. Prognosis of Acute Subdural Hematoma in the Elderly: A Systematic Review. J Neurotrauma. 2019 Feb 15;36(4):517-522. doi: 10.1089/neu.2018.5829. Epub 2018 Aug 14. PMID: 29943683. Link Manivannan S, Spencer R, Marei O, Mayo I, Elalfy O, Martin J, Zaben M. Acute subdural haematoma in the elderly: to operate or not to operate? A systematic review and meta-analysis of outcomes following surgery. BMJ Open. 2021 Dec 3;11(12):e050786. doi: 10.1136/bmjopen-2021-050786. PMID: 34862284; PMCID: PMC8647543. Link  Kuhn EN, Erwood MS, Oster RA, Davis MC, Zeiger HE, Pittman BC, Fisher WS 3rd. Outcomes of Subdural Hematoma in the Elderly with a History of Minor or No Previous Trauma. World Neurosurg. 2018 Nov;119:e374-e382. doi: 10.1016/j.wneu.2018.07.168. Epub 2018 Jul 30. PMID: 30071339. Link MdCalc Canadian CT Head tool   BBC Article about Dame Jilly Cooper   www.rnzcuc.org.nz podcast@rnzcuc.org.nz https://www.facebook.com/rnzcuc https://twitter.com/rnzcuc   Music licensed from www.premiumbeat.com Full Grip by Score Squad   This podcast is intended to assist in ongoing medical education and peer discussion for qualified health professionals.  Please ensure you work within your scope of practice at all times.  For personal medical advice, always consult your usual doctor 

Economists and investors have long turned to copper as a reliable economic indicator: High prices meant the economy was humming, and low prices meant it wasn't. That's in part because copper is useful for so many economic activities. In fact, copper was considered such a good signal that investors gave it a nickname—Dr. Copper. But now, as high demand and tariffs affect copper prices, is the commodity's relationship with the economy becoming blurry? Host Alex Ossola discusses this with Dec Mullarkey, head of investment strategy and asset allocation at SLC Management. This is part two of our four-part series on alternative economic indicators. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

We answered your questions — on Michgian State basketball, lineup decisions, the prognosis for this MSU season and the addition of new recruit Jasiah Jervis, on MSU football and the decisions ahead with Jonathan Smith, and how the Luke Fickell situation is similar and different, on the Tigers, Lions, MSU hockey and the Big Ten Network's issue with hockey, on fighting with your spouse, crimes we've committed and more. 

My guest is Dr. Sunita Puri, a palliative-care physician and author of That Good Night: Life and Medicine in the Eleventh Hour. We talk about what it really means to care for patients when cure is no longer the goal, why our medical system resists honest conversations about death, and how clarity and compassion can coexist at the end of life. Topics we cover:     • What palliative care really provides (beyond hospice)     • Why "more treatment" ≠ "more life"     • Prognosis, probabilities, and telling the truth kindly     • How families can ask the right questions     • Documentation that matters (and what to avoid)     • The moral distress of clinicians     • Cultural/faith factors that shape decisions     • Dignity, autonomy, and realistic hope Guest Bio: Dr. Sunita Puri is an Associate Professor of Medicine at the University of California, Irvine School of Medicine, where she is the Director of the Inpatient Palliative Care Service. She has written for The New Yorker, The New York Times, and The Atlantic, among other publications. She is the author of That Good Night: Life and Medicine in the Eleventh Hour, a critically acclaimed literary memoir examining her journey to the practice of palliative medicine, and her quest to help patients and families redefine what it means to live and die well in the face of serious illness.

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners.This episode covers Functional Neurological Disorder with Dr. Patricia Rosebush. Dr. Rosebush is a Professor in the Department of Psychiatry & Behavioural Neurosciences at McMaster University. She is the distinguished author of numerous articles on clinical neuroscience, including considerable work on mitochondrial disorders in mental illness and over 30 papers on catatonia, and practices consultation-liaison psychiatry at St. Joseph's Healthcare Hamilton.The learning objectives for this episode are as follows:Provide a definition and conceptual approach to FNDIdentify clinical signs and patient histories relevant to a diagnosis of FNDDescribe an approach to the treatment of FNDUnderstand the special challenges of communication and collaboration in this illnessGuest: Dr. Patricia RosebushHosts: Dr. Alastair Morrison, Dr. Kate BraithwaiteAudio editing: Dr. Alastair MorrisonShow notes: Dr. Kate BraithwaiteInterview content:(02:39) Learning objectives(03:09) Conceptualization of FND(08:30) Underlying psychological processes(09:35) Difference between FND and factitious disorder/malingering(14:54) Alexithymia(16:51) Common symptomatic presentations(18:00) Types of underlying stressors(19:17) Other risk factors for FND(22:12) Communicating with patients to address stigma(24:32) Psychotherapy in FND(29:36) Referral pathways for patients with FND(31:15) Prognosis of FND(33:09) Social media and FNDResources:Functional Neurological Disorder Society. Functional Neurological Disorder Society (FNDS). Includes a podcast and courses for physiciansFunctional Neurological Disorder (FND) – A Patient's Guide to FNDReferences:Hull, M., & Parnes, M. (2021). Tics and TikTok: Functional Tics Spread Through Social Media. Movement disorders clinical practice, 8(8), 1248–1252. https://doi.org/10.1002/mdc3.13267National Institute for Neurological Disorders and Stroke. (2024, July.) Functional Neurological Disorder.  U.S. Department of Health and Human Services, National Institutes of Health. Functional Neurologic Disorder | National Institute of Neurological Disorders and StrokePsychDB. (2024, April). Conversion Disorder (Functional Neurological Disorder. Conversion Disorder (Functional Neurological Disorder) - PsychDBRosebush, P. I., & Mazurek, M. F. (2011). Treatment of conversion disorder in the 21st century: have we moved beyond the couch?. Current treatment options in neurology, 13(3), 255–266. https://doi.org/10.1007/s11940-011-0124-yScamvougeras, A., & Castle, D. (2024). Functional Neurological Disorders: Challenging the Mainstream Agnostic Causative Position. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 69(7), 487–492. https://doi.org/10.1177/07067437241245957For more PsychEd, follow us on Instagram (@psyched.podcast),  Facebook (PsychEd Podcast), X (@psychedpodcast), and Bluesky (@psychedpodcast.bsky.social‬). You can email us at psychedpodcast@gmail.com and visit our website at psychedpodcast.org.

What happens when a doctor gives you six months before a wheelchair? Bitsy Hamilton said no. In this powerful episode, Bitsy shares her journey from teacher to ICF-certified life coach while battling a devastating MS diagnosis. She refused the prognosis. Through radical self-advocacy, inflammation control, and daily creative practice, she achieved completely clear MRIs five years later. Her Own It Framework emerged from navigating career shifts, divorce, and health challenges simultaneously. "If you don't have your health, you don't have anything," her father told her. She listened. Now through EA Hamilton Coaching, Bitsy helps others navigate major transitions. Her question for you: Who do you want to be authentically at the end of this transition?Elizabeth "Bitsy" Hamilton is an ICF-certified life coach, author of the forthcoming Own It: A Guide to Confidence, Clarity, and Unshakable Trust, and founder of EA Hamilton Coaching and Consulting. With over 20 years as an educator and coach, she guides individuals through major life transitions using her signature Own It Framework. After defying a devastating MS prognosis through radical self-advocacy, Bitsy now helps clients navigate divorce, career shifts, and identity rediscovery. A Forbes Coaches Council member and upcoming TEDx speaker, she lives in Austin, Texas, blending traditional coaching with nature-based methodologies while maintaining her lifelong creative practice.About The Show: The Life in Transition, hosted by Art Blanchford focuses on making the most of the changes we're given every week. Art has been through hundreds of transitions in his life. Many have been difficult, but all have led to a depth and richness he could never have imagined. On the podcast Art explores how to create more love and joy in life, no matter what transitions we go through. Art is married to his lifelong partner, a proud father of three and a long-time adventurer and global business executive. He is the founder and leader of the Midlife Transition Mastery Community. Learn more about the MLTM Community here: www.lifeintransition.online.In This Episode: (00:00) Refusing the MS Prognosis(01:04) Teaching Career to Life Coaching Transition(08:28) Rediscovering Creativity Through Art(16:41) MidLife Transition Mastery Ad(22:21) Creative Expression as Emotional Healing(26:46) The MS Diagnosis Journey(30:15) Six Months to a Wheelchair Warning(34:02) Taking Control Through Self-Advocacy(42:50) Transition Mastery Coaching Ad(48:44) Hope and Working for What You Want(50:20) The Own It Framework Question(57:23) Finding Your Spark and ClosingLike, subscribe, and send us your comments and feedback.Resources:Website: https://coachbitsy.comInstagram: @coachbitsyLinkedIn: https://www.linkedin.com/in/elizabeth-anne-hamiltonForthcoming Book: Own It: A Guide to Confidence, Clarity, and Unshakable Trust (Winter 2025)Email Art BlanchfordLife in Transition WebsiteLife in Transition on IGLife in Transition on FBJoin Our Community: https://www.lifeintransition.online/My new book PURPOSEFUL LIVING is out now. Order it now: https://www.amazon.com/PURPOSEFUL-LIVING-Wisdom-Coming-Complex/dp/1963913922Explore our website https://lifeintransitionpodcast.com/ for more in-depth information and resources, and to download the 8-step guide to mastering mid-life transitions.The views and opinions expressed on the Life In Transition podcast are solely those of the author and guests and should not be attributed to any other individual or entity. This podcast is an independent production of Life In Transition Podcast, and the podcast production is an original work of the author. All rights of ownership and reproduction are retained—copyright 2025.

Dr. Kelly Makielski and Dr. Jaime Modiano from the University of Minnesota join us on OsteoBites to discuss comparative extracellular vesicle (EV) biomarkers for osteosarcoma risk and prognosis.They are investigating extracellular vesicle (EV) transcriptomic profiles as minimally invasive biomarkers in canine and pediatric osteosarcoma in two ongoing studies. In the Canine Osteosarcoma Early Detection (COED) study, they are sequencing EV RNA from otherwise healthy dogs in breeds at elevated risk of osteosarcoma to identify gene signatures for the early detection and risk assessment of osteosarcoma. In parallel, they are conducting the KIDsCAN study, where we are sequencing EVs from pediatric osteosarcoma patients to identify prognostic signatures that could ultimately guide treatment intensity, aiming to minimize long-term therapy-associated morbidity without negatively impacting survival. Preliminary results from COED will be shared, along with how their comparative approach is helping to guide the KIDsCAN study.Kelly M. Makielski, DVM, DACVIM (SAIM) is an Assistant Professor of Small Animal Internal Medicine at the University of Minnesota College of Veterinary Medicine and Masonic Cancer Center. Her research focuses on extracellular vesicle (EV) biology and comparative oncology, using naturally occurring cancers in dogs to inform human cancer biology and treatment. She is the recipient of an NIH K01 investigating EV–based biomarkers for osteosarcoma prognosis in pediatric osteosarcoma, to guide personalized therapy and reduce treatment-related morbidity.Dr. Jaime Modiano holds the Alvin and June Perlman Endowed Chair of Animal Oncology and is director of the Animal Cancer Care and Research Program of the College of Veterinary Medicine and the Masonic Cancer Center, University of Minnesota. He completed his training through the Veterinary Medical Scientist Training Program (VMD, PhD) at the University of Pennsylvania, and he followed it with a residency in Clinical Pathology at Colorado State University and a post-doctoral fellowship at the National Jewish Center for Immunology and Respiratory Medicine. Before joining the University of Minnesota, he served on the faculties of Texas A&M University and the University of Colorado Health Sciences Center. Dr. Modiano has also worked in the private sector, as founder of several start-up companies, and as Director of Cancer Immunology and Immunotherapy for the Donald Monk Cancer Research Foundation. Through his research, Dr. Modiano seeks to understand how and why cancer happens and to develop strategies for improving the health and well-being of companion animals and humans alike.

Guest: David Feller-Kopman, MD Cytology via thoracentesis remains the first-line approach for diagnosing malignant pleural effusion (MPE), yet its sensitivity is limited. leaving many patients undiagnosed or delayed in treatment. In this expert-led discussion, Dr. David Feller-Kopman explores the limitations of current diagnostic methods and the evolving role of biomarkers in enhancing both diagnostic accuracy and prognostic insight. Dr. Feller-Kopman is a Professor of Medicine at the Geisel School of Medicine at Dartmouth and the Chief of Pulmonary and Critical Care Medicine at Dartmouth-Hitchcock Medical Center, and he discussed this topic at the 2025 CHEST Annual Meeting.

Navigating Autism and End of Life: A Conversation with Dr. Caroline EltonIn this episode of The Girl Doc Survival Guide, host Christine invites back psychologist Dr. Caroline Elton, who has extensive experience supporting doctors' emotional wellbeing. Dr. Elton discusses her new book, Looking After: A Portrait of My Autistic Brother, and touches on end-of-life care.00:00 Introduction and Guest Welcome00:59 Discussing 'Looking After: Portrait of My Autistic Brother'01:22 Lionel's Early Life and Autism Diagnosis02:51 Mother Blaming and Historical Context05:09 Lionel's Leukemia Diagnosis and End of Life Care05:57 Challenges of Communicating About Death11:42 Autism Hospital Passport and Caregiving13:03 Reflections on Lionel's Life and Impact16:42 Final Thoughts on End of Life Care for Autistic Individuals

YDDDY InstagramShortya_official We set up at the Abilities Expo Chicago and sat down with Abad, a 23-year-old Chicagoan seeing the convention for the first time, to talk grit, gear, and the joy of sports. Doctors once said he wouldn't walk or talk; today he's walking short distances with braces, rolling long ones with a chair, making sports content, and using a backyard hoop as a meditation mat. It's a Speedcast with heart: the kind of conversation that jumps from all-terrain wheelchairs and grant options to Cubs optimism and the calm that only a clean jumper can bring.We dig into what sacral agenesis actually means day to day—how a missing tailbone touches movement, balance, and even the most basic routines—and why a broken power chair is more than an inconvenience. Abad opens up about playing wheelchair basketball and softball before the pandemic cut seasons short, then finding a rhythm again at home. He shares how posting sports takes on TikTok builds a community that understands both the box score and the backstory.There's purpose threaded through the plays. Abad's message is direct: your disability doesn't define you. He channels that belief into action with his brand YDDDY, directing proceeds to Free Wheelchair Mission to expand access to mobility worldwide. We swap notes on adaptive tech that widens the map—chairs built for sand, setups that reduce fatigue, smarter paths to funding—and celebrate the small routines that protect mental health. If you're into adaptive sports, disability advocacy, mobility tech, or just a great Chicago sports chat, you'll feel at home here.

Barry emphasized the importance of finishing the year strong while laying the groundwork for 2026, comparing it to a sprinter running through the finish line. He introduced five key pillars for success—mindset and resilience, productivity, financial resources, relationships, and vision—and encouraged attendees to self-assess their strengths and gaps. Barry shared strategies like journaling, affirmations, and meditation to build resilience, along with shifting from time management to activity management to maximize productivity. He also highlighted the role of AI and virtual assistants in saving time, reframing expenses as business investments, and being intentional about building supportive networks. Barry urged participants to set a 12-month vision now rather than waiting for January, stressing that clarity of purpose and consistent small improvements (Kaizen) drive growth. He closed by inviting attendees to upcoming events and training, reinforcing that momentum, mindset, and vision are the foundation for long-term success.

Analysts Don Kellogg and Daryl Schoolar discuss the recent ZTE Global Summit & User Congress, including insights on the practical use of AI, 6G development, and global network standardization.00:00 Episode intro 00:27 ZTE event overview 01:40 Current and future AI network applications 05:44 How much AI is too much? 06:13 The state of the international market 07:56 Operators need the “next big thing” 09:01 ZTE's Pre6G prototype and 6G development 11:38 Prognosis for global network standardization 13:37 Episode wrap-upTags: telecom, telecommunications, wireless, prepaid, postpaid, cellular phone, Don Kellogg, Daryl Schoolar, ZTE, AI, network, automation, LLMs, microloans, gaming, video, China, 5G, slicing, private networks, B2B, 6G, hardware

  Summary In this conversation, Amas Tenumah and Bob Furniss discuss the evolution of contact centers, the impact of CRM systems like Salesforce, and the role of AI in enhancing agent performance. They reflect on the historical context of CRM, the challenges faced by agents, and the future of customer service technology, particularly focusing on the Agent Force initiative. The discussion also touches on the sentiment within the Salesforce community and the potential for new competitors in the market.   Takeaways Salesforce has become a dominant player in the CRM space. The evolution of contact centers has been significant over the years. AI can enhance agent performance rather than replace them. Understanding customer needs is crucial for effective service. The Agent Force initiative aims to improve agent capabilities. There is a negative sentiment towards Salesforce in the contact center community. The cost of building technology is decreasing, making competition more feasible. AI's role in customer service is still evolving and needs to focus on agents. Salesforce must communicate its value to agents to maintain loyalty. The future of customer service technology is uncertain but full of potential. Chapters 00:00 Introduction and Context Setting 01:29 The Evolution of CRM and Contact Centers 06:05 Current Trends in Salesforce and AI 11:13 Agent Force and the Future of Customer Service 15:54 Prognosis for Salesforce and the Industry

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, is joined by Natasha Mesinkovska, MD, associate professor of Dermatology at UC Irvine, to discuss the multifaceted challenges of alopecia areata (AA), an autoimmune condition with complex comorbidities and broad psychosocial implications. The conversation begins with the stigma of hair loss and the importance of addressing the patient's emotional well-being. Dr Mesinkovska highlights her approach: asking simple but direct questions about how patients are coping and connecting them with mental health resources when needed. Comorbidities and workup are also addressed, with Dr Mesinkovska sharing her pragmatic approach to labs: thyroid-stimulating hormone test as a baseline, selective additional testing for patients with indicators of comorbidities, and requesting consultation with endocrinology when indicated. Prognosis is also discussed, with childhood onset and family history noted as adverse factors. They next explore treatment expectations, beginning with the typical timeline of response seen with oral JAK inhibitors and the importance of allowing several months for optimal hair regrowth. Many patients, once regrowth occurs, ask when they can stop therapy in hopes that results will persist without ongoing treatment; this is an important moment to counsel patients on the chronic nature of AA and emphasize that discontinuing therapy often leads to renewed hair loss. Continuing oral JAK inhibitor therapy offers the greatest likelihood of maintaining regrowth over time.  They review clinical data on the durability of response of the JAK inhibitors for AA, which has shown that relapse of hair loss is common once treatment is discontinued. For those who elect to stop therapy, it is essential to emphasize the need to resume treatment promptly at the first signs of relapse, under supervision of their dermatologist. Ongoing clinical and laboratory monitoring is also highlighted as critical to ensure long-term safety. Dr Mesinkovska then discusses differential diagnoses for AA, covering lichen planopilaris, trichotillomania, and other mimickers, with biopsy reserved for challenging cases. She next reviews the 3 approved JAK inhibitors for AA, baricitinib, ritlecitinib, and deuruxolitinib, highlighting differences in efficacy, dosing, speed of response, and the role of CYP2C9 testing specific to deuruxolitinib. Clinical study data are used to outline the features that distinguish deuruxolitinib, the newest oral JAK inhibitor, from the other agents. These include a potentially faster onset of hair regrowth, enhanced efficacy with twice-daily dosing, and the ability to identify individuals who metabolize the drug more slowly through CYP2C9 testing. Tune in to the full episode to hear how dermatologists can assess comorbidities, select systemic therapies, manage patient expectations, and support the psychosocial needs of those with AA to achieve more comprehensive care.

Dr. Monty Pal and Dr. Matteo Lambertini discuss a compelling global study on the clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, the association of pre-diagnostic awareness of BRCA status with prognosis, and the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants. TRANSCRIPT Dr. Monty Pal: Well, hello everyone, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. Now, when we think about genetic testing, whether for patients diagnosed with breast cancer or for other family members of them, it seems to be widely underutilized. Today, we're going to be discussing a recently published study in the Journal of Clinical Oncology that reported on the clinical behavior of breast cancer and specifically young BRCA1 and BRCA2 carriers, and the association of pre-diagnostic awareness of BRCA status with prognosis. I thought this was just a fascinating piece, and I honestly couldn't wait to have this conversation. It's a really compelling paper that highlights the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants, and really the need for genetic counseling and testing to inform people about early detection that could lead to a better prognosis. I'm really delighted to welcome the study's lead author, Dr. Matteo Lambertini. He really needs no introduction. He's very well known in the breast cancer world for his amazing contributions to fertility in the context of breast cancer, to pregnancy in the context of breast cancer, and genetic testing. He's an associate professor at the University of Genova, and a breast cancer medical oncologist at the San Martino Polyclinic Hospital in Genova, Italy.  Dr. Lambertini, thank you so much for joining us today. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a great pleasure. Dr. Monty Pal: Oh, thanks. And just FYI, if you're listening in and you want to hear our disclosures, they're all listed at the transcript of this podcast.  So, I poured through this paper [Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status] yesterday, Dr. Lambertini, and first of all, congratulations on this study. This was a huge international multicenter effort, 4,752 patients. How did you pool all these patients with young breast cancer? Dr. Matteo Lambertini: Thanks a lot for the question. Yes, this was an effort made by several centers all over the world. The main idea behind the creation of this network that we have named as BRCA BCY Collaboration, was to get as many data as possible in a sort of niche patient population in the breast cancer field, meaning women diagnosed with breast cancer at the age of 40 years or younger, and all of them being BRCA carriers. We know that around, in the Western world, around 5% of breast cancer cases are being diagnosed under the age of 40 years, and among them around 10-15% are BRCA carriers. So, I would say it's a relatively rare patient population where we did not have a lot of evidence to support our choices in terms of counseling on treatment, prevention, and oncofertility as well. That was the idea behind the creation of this network that includes many centers. Dr. Monty Pal: Yeah. You know, what's so interesting about this is that you sort of draw this line between patients who have BRCA testing at the time of diagnosis and then BRCA testing earlier in their course and then leading to a diagnosis perhaps. And I think that's where really sort of the dichotomy in outcome sits. Can you maybe elaborate on this and tell us about timing of genetic testing in this study and what that meant ultimately in terms of prognosis? Dr. Matteo Lambertini: In this specific analysis from this large network, including almost 5,000 women with breast cancer diagnosed at the age of 40 years or younger and being a BRCA carrier, we looked specifically into the timing of genetic testing because this is a retrospective study and the criteria for inclusion are those that I have just mentioned, so diagnosis at a young age plus carrying germline BRCA pathogenic or likely pathogenic variant. In this analysis, we have looked into the time the patient has got the genetic testing and particular we focused on two populations: those that were diagnosed, knowing already to be a BRCA carrier, and those that got tested after being diagnosed with breast cancer. And the main findings from this analysis have been that knowing to be a BRCA carrier was associated with a lower stage at the time of diagnosis, meaning more T1 tumors, so a tumor less than 2 cm, more node-negative disease, and this translated into less aggressive treatment, so less often axillary dissection, less often use of chemotherapy and anthracycline-based chemotherapy. And even more importantly, we have seen a better overall survival for those patients that were diagnosed already knowing to be BRCA carriers as compared to those tested after breast cancer diagnosis. These results after adjusting for all the confounding, stage, treatment and so on, there was not significant anymore, meaning that it's not the timing of test per se that is probably leading to a better survival, but it is the fact that knowing to be a BRCA carrier would likely translate into having access to all the preventive measures that we have in this setting and this will translate into an overall survival benefit, so in terms of saving more lives in young BRCA carriers. Dr. Monty Pal: I think it's such an important point, and it's one that I think might sound implicit, right, but it needs to be proven, I think, through a study like this. You know, the fact that finding this early, identifying the mutation, doing enhanced screening, and so forth, is really going to lead to superior clinical outcomes. One of the things that I think many people puzzle over, including myself, is what to do? I personally occasionally will see BRCA altered patients in the context of prostate cancer. But that's a very different population of individuals, right? Typically older men. In young females with BRCA mutation, I guess there's a specific set of considerations around reproductive health. You'd already highlighted preventive strategies, but what sorts of things should we be talking about in the clinics once a patient's diagnosed and once perhaps their breast cancer diagnosis is established? Dr. Matteo Lambertini: Yes, exactly. Knowing to be a BRCA carrier has a lot of implications from prevention to treatment to survivorship issues including reproductive counseling. And this is important not only for the patient that has been diagnosed with breast cancer but also for all the family members that will get tested and maybe identify with this sort of genetic alteration before diagnosis of cancer. Why this is important is because we have access to very effective preventive measures, a few examples: MRI screening, which starts at a very young age and normally young women don't have an effective screening strategy outside the BRCA field. Also, primary preventive measures, for example, risk-reducing surgery. These women are known to have a high risk of breast cancer and high risk of ovarian cancer. So the guidelines are suggesting to undergo risk-reducing salpingo-oophorectomy at a young age, so 35 to 40 years in BRCA1 carrier, 40 to 45 years in BRCA2 carrier. And also risk-reducing mastectomy should be discussed because it is a very effective way to prevent the occurrence of breast cancer. And in some situations, including the setting that we are talking about, so young women with breast cancer, BRCA carrier, also risk-reducing mastectomy has shown to improve overall survival.  On the other side, once diagnosed with breast cancer, nowadays knowing to be or not a BRCA carrier can make a difference in terms of treatment. We have PARP inhibitors in the early setting, in the adjuvant setting as well as in the metastatic setting. And in terms of survivorship implication, one of the critical aspects for young women is the oncofertility care which is even more complicated when we talk about BRCA carriers that are women candidates for gynecological surgery at a very young age. So this sort of counseling is even more complicated. Dr. Monty Pal: One of the other things, and this is subtle in your paper and I hope you don't mind me bringing it up, is the difference between BRCA1 and BRCA2. It really got me thinking about that because there are differences in phenotype and manifestation. Do you mind just expanding on that a little bit for the audience because I think that's a really important reminder that you brought up in the discussion? Dr. Matteo Lambertini: The difference between BRCA1 and BRCA2 carriers has been known that there are different phenotypes of breast cancer that are more often diagnosed in these two different populations. Normally BRCA1 carriers have a higher likelihood to develop a triple negative breast cancer as compared to BRCA2 carriers, more likely to develop a hormone receptor-positive HER2-negative disease. In this study, again, a specific population of young women with breast cancer, we have seen the same findings, mostly triple negative disease in BRCA1 carrier, mostly luminal-like disease in BRCA2 carrier. But what's novel or interesting from this study is to look also at the age at the time of diagnosis of this disease. And particularly in BRCA1 carriers, we should be sort of more careful about diagnosis of breast cancer and also other primary tumors including ovarian cancer because the risk of developing these malignancies is higher even at a younger age as compared to BRCA2 carriers. And this has implications also in the primary and secondary prevention that we were talking about earlier. Dr. Monty Pal: Oh, interesting. I guess the fundamental question then from your paper becomes, how do we get at the right patients for screening for BRCA1 and BRCA2? And I realize our audience here is largely oncologists who are going to be listening to this podcast, oncology providers, MDs, nurses, etc. But maybe speak for a moment to the general practitioner. Are there things that, for instance, a general practitioner should be looking for to say, “Wait a minute, this patient's high risk, we should consider BRCA1, BRCA2 testing or germline screening”? Dr. Matteo Lambertini: Yes, it's a very important question for the breast cancer community. After the updated ASCO guideline, the counseling is way easier because right now the age cutoff goes up to 65 years, meaning that all the patients diagnosed with breast cancer below the age of 65 years should be tested these days. And then above the age of 65, there are different criteria like triple-negative disease or family history. From a general practitioner standpoint, it's of course a bit more difficult, but knowing particularly the family history of the person that they have in front will be crucial to know if there are cases of breast cancer diagnosed at a young age, maybe triple-negative cases, knowing cases of ovarian cancer in first-degree relatives or pancreatic cancer in first-degree relatives, and of course cases of prostate cancer as well. So, I would say probably mostly the family side will be important from a general practitioner perspective.  From an oncology one, the other point that I think is important to stress also based on the data that we have shown in this publication is that having a case of breast cancer known to carry a BRCA pathogenic or likely pathogenic variant. It means that all the people around this case should get tested and if found to be BRCA carrier and healthy carrier, these people should also undergo the primary and secondary prevention strategies because this is very critical also to improve their outcomes and try to avoid the developing of breast or ovarian cancer, but also in the case of diagnosis of this disease, a diagnosis at an earlier stage, as we have seen in this paper. Dr. Monty Pal: Brilliant. I'm going to diverge from our list of questions here and close by asking a question that I have at the top of my mind. You're very young. I know our podcast listeners can't see you, but you're very, very young. Dr. Matteo Lambertini: Thank you. Thank you for that. Not so young but yeah. Dr. Monty Pal: You have nearly 300 papers. Your H-index is 67. You've already made these seminal contributions, as I outlined it from the outset, regarding fertility, regarding use of GnRH analogs, regarding pregnancy and breast cancer. What are you studying now? What are you really excited about right now that you're doing that you think might potentially be practice changing? Give us a little teaser. Dr. Matteo Lambertini: Yeah. Thanks a lot, Dr. Pal. Receiving this compliment from you is fantastic. So, thanks a lot for that. From my side, in terms of my research, I've been interested in the field of breast cancer in young women since the start of my training. I've had very good mentors from Italy, from Europe, from the U.S. I'm still interested in this field, so I think we still have a lot to learn to try to improve the care of young women with breast cancer. For example, the oncofertility care, which is something I worked a lot over the past years. Now with all the new treatment options, there's a sort of new chapter of oncofertility counseling. So, what's the impact of immunotherapy? What's the impact of the new targeted agents?  More on the genetic aspects, now we know that there's not only BRCA1 or BRCA2. There are a lot of other different genes that may increase the risk of breast cancer and other malignancies. And also for these genes, we really don't have a lot of evidence to counsel women on prognosis, treatment, prevention strategy. So we need to learn way more for this special patient population that are quite rare, and so we really need a multicenter academic effort to try to give some evidence in this field. Dr. Monty Pal: Yeah. It's tough because these are rare circumstances, but, you know, I think that you've done really well to sort of define some collective experiences that I think really define therapy. I mean, I just remember when I was in training 25 years ago, just reading through textbooks where all the experience around breast cancer and pregnancy was really just very sort of anecdotal almost, you know? And so it's great to see that the state of the science has moved forward.  Well, gosh, I really enjoyed our conversation today. I think your study really reminds us how powerful genetic information is in terms of improving outcomes. And, you know, hopefully this will lead some individuals to perhaps test more broadly in appropriate settings. So, thank you so much, Matteo, for joining us today with your fantastic insights on the ASCO Daily News Podcast. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a real pleasure. Dr. Monty Pal: And thanks to our listeners too. You'll find a link to Dr. Lambertini's study in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks a ton. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal  Dr. Matteo Lambertini @matteolambe   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Monty Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Matteo Lambertini: Consulting or Advisory Role: Roche, Novartis, Lilly, AstraZeneca, Pfizer, MSD, Exact Sciences, Gilead Sciences, Seagen, Menarini, Nordic Pharma Speakers' Bureau: Takeda, Roche, Lilly, Novartis, Pfizer, Sandoz, Ipsen, Knight Therapeutics, Libbs, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Menarini, AstraZeneca, Menarini Research Funding (Inst.): Gilead Sciences Travel, Accommodations, Expenses: Gilead Sciences, Daiichi Sankyo Europe GmbH, Roche

Contributor: Alec Coston, MD Case Report Summary: A 17-year-old female involved in a motor vehicle collision presented to a rural emergency facility via personally operated vehicle. During workup and initial CT scan, the patient began rapidly decompensating with CT revealing a 1.5cm epidural hematoma with 7mm of midline shift. The patient went from being able to walk and talk to being obtunded with a blown left pupil and unresponsive. Following intubation, the patient was being prepared for transport but potential delays required immediate emergency evacuation of the hematoma via a Burr Hole. A traditional Burr Drill was not immediately available at the facility, so an improvised Burr Drill using an Intraosseous (IO) drill was used. 35mL of blood was removed from the hematoma and the patient immediately improved from a GCS of 3 to GCS of 8. The patient was transferred to a higher level of care facility, extubated the following day, and made a full neurological recovery.  Educational Pearls: What is an epidural hematoma? An epidural hematoma is a collection of blood between the dura mater (outermost layer of the meninges) and the skull, whereas a subdural hematoma is a collection of blood between the dura mater and arachnoid mater. Both can be life threatening depending on location and size. Epidural hematomas tend to be arterial, and are typically secondary to trauma and can rapidly expand, but with timely recognition and evacuation of the bleed, favorable outcomes are often possible. What are typical intracranial pressures and at what levels do they become pathologic? Typical intracranial pressure (ICP) varies by age, but past infancy and early childhood, adolescents and adults have a value typically between 8-15mmHg. Values exceeding 20mmHg become pathologic and rise exponentially with increased volume. Initial symptoms may include headache, nausea, and vomiting, but with increased pressures may progress to more life threatening symptoms such as loss of consciousness, cranial nerve palsies, pupillary constriction or dilation (sign of herniation), and respiratory irregularities. What is the takeaway in timing of epidural hematomas? Older studies show that evacuation of a hematoma with lateralizing features before the two hour mark of coma symptom onset is correlated with decreased mortality (ranging from 15-17%), but beyond 2 hours the mortality increases to well over 50%. Though mortality statistics have grown more variable, early targeted evacuation of epidural hematomas still remains critical for improved patient outcomes. In austere conditions with limited resources, improvisation with interosseous drills and needles can improve patient outcomes and achieve the target therapy for epidural hematomas. References Haselsberger K, Pucher R, Auer LM. Prognosis after acute subdural or epidural haemorrhage. Acta Neurochir (Wien). 1988;90(3-4):111-116. doi:10.1007/BF01560563 Hawryluk GWJ, Nielson JL, Huie JR, et al. Analysis of Normal High-Frequency Intracranial Pressure Values and Treatment Threshold in Neurocritical Care Patients: Insights into Normal Values and a Potential Treatment Threshold. JAMA Neurol. 2020;77(9):1150-1158. doi:10.1001/jamaneurol.2020.1310 Pisică D, Volovici V, Yue JK, et al. Clinical and Imaging Characteristics, Care Pathways, and Outcomes of Traumatic Epidural Hematomas: A Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury Study. Neurosurgery. 2024;95(5):986-999. doi:10.1227/neu.0000000000002982 Summarized by Dan Orbidan, OMS2 | Edited by Dan Orbidan and Jorge Chalit, OMS4 Donate: https://emergencymedicalminute.org/donate/

Full article: Central Tumor Location in Resected Lung Adenocarcinoma: Association with Recurrence and Survival Outcomes What is the association of tumor location with lung cancer outcomes? Antonino Andrea Blandino, MD, discusses the article by Ahn et al. exploring prognostic implications of central location for resected lung adenocarcinoma. 

Send us a textIn today's episode of PTs Snacks podcast, hosted by Kasey, we dive into the intricacies of high ankle sprains, also known as syndesmotic ankle sprains. We'll explore the relevant anatomy, common mechanisms of injury, diagnostic techniques, and treatment strategies. Kasey also highlights the importance of distinguishing high ankle sprains from other types of ankle injuries and discusses both non-surgical and surgical management approaches. Whether you're a seasoned physical therapist or a student, this episode is packed with valuable insights to enhance your clinical practice.00:00 Introduction to PTs Snacks Podcast00:19 Understanding High Ankle Sprains00:56 Anatomy Review: Syndesmotic Ligaments03:43 Mechanism of Injury05:29 Clinical Presentation and Diagnosis06:43 Stress Tests for High Ankle Sprains08:29 Imaging and Differential Diagnoses09:30 Treatment and Rehabilitation Stages11:43 Prognosis and Final Thoughts12:19 Special Offers and ConclusionGo to PT Final Exam using this link to access great studying options to conquer the NPTE!Support the showStay Connected! Make sure to hit follow now so you don't miss an episode! Got questions? Email me at ptsnackspodcast@gmail.com or leave feedback HERE. You can also join the email list HERE Need CEUs Fast?Time and resources short? Medbridge has you covered: Get over $100 off a subscription with code PTSNACKSPODCAST: Medbridge Students: Save $75 off a student subscription with code PTSNACKSPODCASTSTUDENT—a full year of unlimited access for less! Prepping for the NPTE? Get all the study tools you need to master it at PT Final Exam. Use code PTSnacks at checkout to get a discount! Want to Support the Show?Help me keep creating free content by: Sharing the podcast with someone who'd benefit. Contributing directly via the link...

Bridging the Gap: Taryn Hallam on Surgery, Pelvic PT, and Honest PrognosisFew people in the pelvic health world have shaped the field like Taryn Hallam. With decades of experience as a clinician, educator, and researcher, she has a unique ability to bridge research and clinical practice.In this episode, we cover:How Taryn's research background in Sydney shaped her pelvic PT lensWhy bridging the gap between surgeons and therapists matters for better outcomesThe importance of prognosticating honestly (and how imposter syndrome gets in the way)Her take on controversial practices like crunches during pregnancy and flow stop exercisesWhy lifelong learning, mentorship, and case studies are essential to growth in pelvic health

Featuring an interview with Prof Xavier Leleu including the following topics: Introduction: Historical treatment advances in multiple myeloma (MM) (0:00) Contemporary treatment for patients with newly diagnosed MM who are eligible for transplant (13:18) Prognosis and life expectancy for patients with MM (19:39) Mechanistic differences among anti-CD38 monoclonal antibodies (27:05) Routes of administration of anti-CD38 monoclonal antibodies (30:21) Background and treatment of smoldering myeloma (41:05) Treatment for older patients with newly diagnosed MM who are not eligible for transplant (46:41) NCPD information and select publications

Sam Libby is a veteran healthcare investment banker and the founder of TCB Capital Advisors. After a long career, he's now dedicated to a single mission: making a real, tangible impact on patient care. Links: ⭐ Sponsored by Podcast10x - Podcasting agency for VCs - https://podcast10x.comTCB Capital Advisors website - https://www.tcbcapitaladvisors.com/Sam Libby on Linkedin - https://www.linkedin.com/in/sam-libby-b4530b48/

Pat Kellett, President of the St Louis Labor Council, joins Michael and Amy and comments on the Boeing strike in St Louis. He says that 'it's time' for Boeing to share their good fortunes with their workers in St Louis.

Learn more about Paths to Understanding at https://www.PathsToUnderstanding.org Join the Paths Network at https://www.PathsNetwork.org New mothers and their infants are more likely to die in the United States than in any European country. The life expectancy of the average American is closer to that of middle eastern or south American countries than counterparts in western or central Europe, and it's been decreasing. Physicians are concerned those trends will continue with federal cuts to healthcare and health research programs. Our guest in this episode of Challenge 2.0 will address those concerns- Seattle-area cardiologist Dr. Mark Vossler, who leads the group Physicians for Social Responsibility.

Send us a textThyroid Talk with Dr. Angela Mazza, DOShow Notes Episode 42; Recorded: 8-8-2025Help for HyperparathyroidismHost: Dr. Angela Mazza, DOCo-host: Dawn Sheffield I'm Dr. Angela Mazza, D.O., a thyroid, endocrine, and metabolism specialist with a private practice in Central Florida.  My goal for this podcast is to define and demystify the thyroid gland, and thyroid-related medical conditions.   Here's some of what we covered today, not necessarily in this order: ·        What are the parathyroid glands, and what do they do?·        Where are the four parathyroid glands located?·        Over-active and under-active parathyroid conditions, compared.·        Do parathyroid glands respond to lifestyle interventions?·        Prognosis and treatment options for hyperparathyroidism.·        How available, and how effective, are treatment options?·        And best of all we learned that we CAN impact our thyroid health!My book, Thyroid Talk: An Integrative Guide to Optimal Thyroid Health, is available on Amazon.  For information on the related Webinar and online master course, see thrivethyroid.com.  Or forward your name and email to thyroidtalk.mazza@gmail.com or to our website: metaboliccenterforwellness.com  The webinar coordinates with the online master class.  The master class has modules that cover topics like diagnosis of thyroid issues, personalized treatment, gut healing, and much more--plus some bonuses. Visit the Wellness Store at metaboliccenterforwellness.com regarding supplements mentioned in various episodes of this podcast.  Please stay in touch!  Send your comments, show ideas, and questions to thyroidtalk.mazza@gmail.com  We may disclose your general location on air (the city or town, for example), but we will NOT read your name NOR your address on the show.  We reserve the right to edit your input as necessary.  See the website at metaboliccenterforwellness.com; our YouTube channel (Dr. Angela Mazza), Facebook, and Instagram.   The topic of our next episode may still be in the planning stages as of this recording. Citations, references, additional information: mayoclinic.org.  Hyperparathyroidism.  Mayo clinic staff.  May 17, 2022.Mazza, A. Thyroid Talk: An Integrative Guide to Optimal Thyroid Health.  Available now on Amazon.Ask your healthcare provider about specific questions regarding your wellness.  This podcast is meant for educational purposes only.Copyright 2025 Dr. Angela Mazza DO.  Thyroid Talk with Dr. Angela Mazza, DO.  All rights reserved. MUSICCopyright 2025 Dr. Angela Mazza DO.  Thyroid Talk with Dr. Angela Mazza, DO.  All rights reserved.   Check out our YouTube channel - Dr. Angela Mazza, our website at Metabolic Center for Wellness, our FaceBook and our Instagram page.

00:00 – 13:34 – Kevin’s rocking a tank top and is disappointed in Marc, British Open, Fever lose to the Liberty and Caitlin Clark remains out, her status for the WNBA All-Star Game, 13:35 – 20:38 – Morning Checkdown 20:39 – 40:58 – The oldest Colt on the roster is surprising, he also appears to be the longest tenured Colt now without Ryan Kelly, NFL rookie contracts, if a team offered the Colts a second-round pick for Alec Pierce should the Colts take it?, Victor Oladipo reuniting with the Pacers?, Fever get smoked by the Liberty last night 40:59 – 1:03:47 – Colts VP of Communications Steve Campbell joins us to discuss the ramp up period to training camp and what is coming to Westfield, what fans can expect to see, one of the few NFL teams still doing training camp off-site, best position of strength on the roster, could Caitlin Clark participate in the 3-point contest and not the All-Star Game?, Stephanie White’s comment on the status of Clark heading into All-Star weekend, bison farms, Morning Checkdown 1:03:48 – 1:15:22– NFL Coach most likely to get fired first this season, Shane Steichen is 3rd on the list and is that fair?, who has the bigger hot seat: Shane Steichen vs. Chris Ballard 1:15:23 – 1:22:09 – Best case scenario for the Pacers next season 1:22:10 – 1:45:51 – Braden Smith’s high school coach and Westfield’s Shane Sumpter joins us to discuss Smith’s strengths, how he looked early on as a player and how he’s developed, his best quality, what he remembers about his recruiting, retiring his number, looking ahead to Westfield’s season, Morning Checkdown 1:45:52 – 1:57:59 – Indiana Fever sideline reporter Kelsie Kasper joins us after an insane day of travel, Caitlin Clark’s latest injury, the WNBA All-Star rule changes and which one she likes, Sydney Colson’s upcoming comedy gig 1:58:00 – 2:02:54 – Wrapping up the show: we give away state fair tickets, Kevin’s tank top jokesSupport the show: https://1075thefan.com/the-wake-up-call-1075-the-fan/See omnystudio.com/listener for privacy information.

In the future, medicine is very comprehensive and very accurate.Another story by Dr. Jeffrey A Robinson, based on a idea by Joseph A. Shiller.

On this episode of Translating Proteomics, Parag, Andreas, and special guest Don Kirkpatrick answer questions submitted by the Translating Proteomics community. They cover:Needs in plasma proteomicsHow proteomics impacts drug development – with special guest Don Kirkpatrick Ph.D.!How lifestyle impacts the proteomeHow the Nautilus Proteome Analysis Platform is impacting tau and Alzheimer's disease researchReferencesShome et al., 2022 - Serum autoantibodyome reveals that healthy individuals share common autoantibodieshttps://www.sciencedirect.com/science/article/pii/S2211124722006489LaBaer Lab paper investigating autoantibody levels in plasma and their relationship to health.Sylman et al., 2018 - A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patientshttps://www.nature.com/articles/s41598-018-25019-1Mallick lab paper investigating temporal changes in platelets and their associations with cancer biology.Krönke et al., 2014 - Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cellshttps://www.science.org/doi/10.1126/science.1244851Seminal paper describing selective protein degradation caused by lenalidomide.Fink and Ebert 2015 - The novel mechanism of lenalidomide activityhttps://ashpublications.org/blood/article/126/21/2366/34644/The-novel-mechanism-of-lenalidomide-activityReview of research elucidating the mechanisms of lenalidomide activityNdoja et al., 2025 - COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathwayhttps://www.mdpi.com/2073-4409/14/13/975Describe links between kinase inhibitor vemurafenib and changes in ETV transcription factor degradationSong et al., 2022 - RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacyhttps://aacrjournals.org/cancerdiscovery/article/12/1/204/675622/RTK-Dependent-Inducible-Degradation-of-Mutant-PI3KUse proteomics to discover that inavolisib acts through selective degradation of mutant PI3KαCanon et al., 2019 - The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityhttps://www.nature.com/articles/s41586-019-1694-1Covers the development of an inhibitor of KRAS mutant KRAS (G12C).Schneider et al., 2024 - Feeding gut microbes to nourish the brain: unravelling the diet-microbiota-gut-brain axishttps://www.nature.com/articles/s42255-024-01108-6Review on the gut-brain axisWebpage for Johanna Lampe's Lab at Fred Hutch Cancer Center

I'm never excited when I diagnose a cat with anaemia: vague signs, confusing diagnostics, and what feels like a not-so-great prognoses. But are they really that hopeless?In this episode, feline medicine specialist Dr Rachel Korman joins us demystify the anaemic cat and offer a clear, practical diagnostic framework that will give you more confidence and better outcomes the next time you see a cat with a low PCV.Some highlights from this conversation:A step-by-step approach to categorising anaemia.Regenerative vs. non-regenerative: what it actually means in cats, and how to interpret the data.Why IMHA in cats doesn't look like IMHA in dogs — and how to recognise it.Haemoplasma infections (like Mycoplasma):  When to treat, how to treat, PCR testing, and what the results really tell you.Age-specific differentials: what to prioritise in young vs. older cats.Supportive care: what works, what's myth.Prognosis pitfalls: why PCV alone doesn't predict survival.This episode will help you approach feline anaemia with more clarity, structure, and - dare we say - optimism.

Jeff Blair and Kevin Barker kick off the second hour with Los Angeles Dodgers President and CEO Stan Kasten (1:30). He discusses why so many Dodgers pitchers are getting hurt, how they mitigate the risks associated with Shohei Ohtani pitching, their rivalry with the Padres, and the challenge of managing multiple superstars for Dave Roberts. Then, Jeff and Kevin react to Blue Jays manager John Schneider's pregame availability, where he discussed Alek Manoah's progress and Yimi García's looming return. Finally, Jeff and Kevin go to the Back Leg Line to answer your calls and questions!The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliates.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AZC865. CME credit will be available until 19 June 2026.Navigating the Layers of Complexity in R/R B-Cell Cancers: From Clinical Prognosis to Emerging Therapeutic Prospects in CLL/SLL, MCL, and DLBCL In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AZC865. CME credit will be available until 19 June 2026.Navigating the Layers of Complexity in R/R B-Cell Cancers: From Clinical Prognosis to Emerging Therapeutic Prospects in CLL/SLL, MCL, and DLBCL In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

In this podcast, Dr. Adam Khader (Richmond VA Medical Center & Assistant Professor at VCU School of Medicine) moderates a focused discussion with Dr. Jula Veerapong (UC San Diego Health) and Dr. Zachary Brown (NYU Langone Medical Center) on the clinical assessment and treatment of goblet cell carcinoma (GCC). The panel explores how evolving pathologic classifications impact management, the role of staging, and treatment considerations including systemic therapy and surgery. This episode provides practical, expert-driven insights for clinicians managing patients with this rare appendiceal malignancy.

Featuring perspectives from Dr Farshid Dayyani, Ms Caroline Kuhlman, Dr Philip A Philip and Ms Amanda K Wagner, including the following topics: Introduction: Initial Management of Pancreatic Adenocarcinoma (PAD) (0:00) Clinical Presentation and Prognosis of PAD; Recent Advances in Up-Front Treatment for Metastatic PAD (19:01) Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (54:38) Importance of Palliative Care for Advanced PAD (1:06:09) Role of PARP Inhibitor Maintenance Therapy for Newly Diagnosed Metastatic PAD (1:14:59) Promising Investigational Strategies for PAD (1:26:56) NCPD information and select publications

In this episode, Dr. Zanotti discusses the science of hope. He's joined by Dr. Stephen Trzeciak, a physician-scientist, the Edward D. Viner Endowed Chief of Medicine at Cooper University Health Care, and Professor and Chair of Medicine at Cooper Medical School of Rowan University in Camden, New Jersey. Dr. Trzeciak is a practicing intensivist and a clinical researcher with more than 100 publications in the scientific literature. In addition, he is co-author of two excellent books: Wonder Drug: 7 Scientifically Proven Ways That Serving Others Is the Best Medicine for Yourself (2022) and Compassionomics: The Revolutionary Scientific Evidence that Caring Makes a Difference (2019). Additional resources: Recovery Expectations and Long-term Prognosis of Patients with Coronary Heart Disease Barefoot JC, et al. JAMA Internal Medicine 2011: https://pubmed.ncbi.nlm.nih.gov/21357800/ Optimism and Rehospitalization After Coronary Artery Bypass Graft Surgery. Scheler MF, et al. JAMA Int Med 1999: https://pubmed.ncbi.nlm.nih.gov/10219928/ The median is not the message. By Jay Gould: https://journalofethics.ama-assn.org/sites/joedb/files/2018-05/mnar1-1301.pdf Books mentioned in this episode: Man's Search for Meaning. By Viktor E. Frankl: https://bit.ly/3SqsNyt Wonder Drug: 7 Scientifically Proven Ways That Serving Others Is the Best Medicine for Yourself. By Stephen Trzeciak and Anthony Mazzarelli: https://bit.ly/4kiyA5q Compassionomics: The Revolutionary Scientific Evidence that Caring Makes a Difference. By Stephen Trzeciak and Anthony Mazzarelli: https://bit.ly/43ul5IE

Drs. Bose and Pemmaraju review secondary myelofibrosis arising from polycythemia vera or essential thrombocythemia and how it differs from primary myelofibrosis that develops de novo.

Our main focus today was on nudging critical care clinicians to consider a more palliative approach to care.  Our guests are all trained in critical care: Kate Courtright, Scott Halpern, and Jaspal Singh.  Kate and Scott have additional training in palliative medicine.  To start. we review: What is a nudge? Also called behavioral interventions, heuristics, and cognitive biases. Prior podcasts on the ethics of nudging, and a different trial conducted by Kate and Scott in which the default for hospitalized seriously ill patients was to receive a palliative care consult. What is sludge?  I'd never heard the term, perhaps outside of Eric's pejorative reference to my coffee after adding copious creamers, flavoring, and sweeteners.  Sludge is apparently when you create barriers or extra work for someone.  For example, putting the healthy food at the back of the grocery store is sludge; making an applicant for health insurance climb the flight of stairs to the office - weeding out those less fit - is also sludge.  Prior-auth forms? Sludge. Examples of nudges, some based in health care, others in coffee.  This specific study, published in JAMA Internal Medicine, was conducted in 17 ICUs in North Carolina. Many were community hospitals.  Participants were critically ill and intubated.  Clinicians were randomized to 4 groups: Usual care Prognosis nudge - EHR prompt asking, do you think your patient will be alive in 6 months? This is called a focusing effect Comfort care nudge - EHR prompt asking if they'd offered comfort-focused care. This is called accountable justification - an appeal to standards of care for critically ill patients endorsed by multiple professional societies. Both the prognosis and comfort care nudge. A few key points of discussion: Is an EHR prompt a nudge or sludge?   The intervention was a negative study for the primary outcome, hospital length of stay.  Why?  The prognosis nudge did nothing.  What to make of that? Would you think an EHR nudge to consider prognosis might move the needle, at least on some outcomes? The nudge toward offering comfort care led to more hospice and early comfort-care orders.  Is this due to chance alone, given the multiplicity of secondary outcomes examined?  Or is it a tantalizing finding that suggests a remarkably low cost EHR based nudge might, on a population level, lead to critical care clinicians offering comfort care and hospice more frequently?  Imagine!    -Alex Smith  

  On this episode of Unsupervised Learning Razib talks to Matt Welch. He co-founded the Prague-based newspaper Prognosis in the early 1990's and later worked as an opinion section editor for the Los Angeles Times. From 2008-2016, Welch served as editor-in-chief of Reason magazine, where he currently holds the position of editor-at-large. He co-authored The Declaration of Independents: How Libertarian Politics Can Fix What's Wrong with America and wrote McCain: The Myth of a Maverick. Today, Welch co-hosts The Fifth Column podcast with Kmele Foster and Michael Moynihan. Razib and Welch first go back to his days in Eastern Europe, and how they shaped his views on foreign policy, making him somewhat heterodox for someone whose primary political inclinations favor libertarianism. Welch discusses how wild, hopeful and chaotic the 1990's were in the former Eastern Bloc after the fall of the Iron Curtain and the end of Communism. He also argues that these nations had strong historic and contemporary geopolitical reasons to fear the former Soviet Union, and so pushed for the eastward expansion of NATO. Razib makes the Russian case that its turn away from the West in the 2000's was in response to America's strategy of encirclement, but Welch dismisses this as Russian revisionism. He believes that at the end of the day Soviet-era elites retained an imperial attitude toward Eastern and Central Europe rooted in a centuries-long assumption of Russian hegemonic status in the region. Next, retreating from abstruse foreign policy, Razib and Welch discuss the early days of the blogosphere, in 2001/2002. Then, Welch coined the term “warblogger,” and envisaged a scenario where post-partisan citizen-journalists would play an essential role in the information ecosystem of the 21st century. He discusses his disappointment with the reemergence of partisanship within the blogosphere, as well as the disappointments of post-9/11 interventionism. Welch also talks about the Tea Party, and its connection, and ultimate disconnect, from libertarianism. They also discuss how the Tea Party energy was eventually transferred to the ideologically heterodox and often anti-libertarian Trump movement. Finally, Welch talks about his latest primary venture, the successful The Fifth Column podcast. Razib asks if the current age of podcasting is analogous to the early blogosphere. Welch talks about how organically and gradually The Fifth Column came into being, and the growing pains with greater professionalization. He also addresses their future on The Fifth Column, with a new shift toward video, while continuing the informal and candid nature of the discussions.